Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis

Thomas Gärtner, Sandra Crnko, Laurynas Leiteris, Iris van Adrichem, Linda W. van Laake, Carlijn V. C. Bouten, Marie‐José Goumans, Willem J.l. Suyker, Joost P. G. Sluijter, Jesper HjortnaesFrontiers in Cardiovascular Medicine 2022 · DOI

TL;DR

Researchers have developed a novel 3D in vitro model of human cardiac fibrosis using a tunable hydrogel, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), and cardiac fibroblasts. This model successfully replicated fibrotic responses and was used to demonstrate that the anti-fibrotic drug pirfenidone exhibits beneficial effects, though it doesn't fully reverse all TGF-β1-induced fibrotic changes, offering new insights into its mechanism.

What Problem Does This Paper Address?

Heart failure is often accompanied by cardiac fibrosis, a process where excessive extracellular matrix (ECM) deposition stiffens the heart and impairs its function. Current treatments for heart failure primarily manage symptoms and do not directly target or reverse this fibrosis. Developing effective anti-fibrotic therapies is challenging because many promising drug candidates fail in human clinical trials, highlighting a need for better preclinical models. Specifically, understanding how drugs like pirfenidone, already used for idiopathic pulmonary fibrosis, work in the context of human cardiac fibrosis and identifying its precise molecular targets has been limited.

Methods

The core of this study is the development and application of a 3D tissue-engineered model of human cardiac fibrosis.

  • Scaffold: A gelatin methacryloyl (GelMA) hydrogel was used as the scaffold. This material is advantageous because its mechanical properties (specifically, its elastic modulus) can be precisely tuned by adjusting the GelMA concentration and UV crosslinking parameters. The researchers found that a 7.5% GelMA concentration provided an elastic modulus (around 7 kPa) that mimics the stiffness of a healthy heart, which is crucial for proper cell function.
  • Cellular Components: The model incorporates two key cell types:
  • Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs): These cells were differentiated from iPSCs and cultured to achieve high purity (>95%).
  • Human fetal cardiac fibroblasts (hfCFs): These primary cells are known to be the main drivers of cardiac fibrosis.
  • Construct Fabrication: hiPSC-CMs and hfCFs were mixed within the GelMA solution along with a photo-initiator and then crosslinked using UV light to form 3D cardiac tissue constructs (CTCs).
  • Optimization: Significant effort was dedicated to optimizing the cell density and the ratio of hiPSC-CMs to hfCFs to achieve synchronous beating throughout the construct, indicating functional integration and electromechanical coupling. They found that a cell density of 28-50 million cells/mL with a 70-80% hiPSC-CM ratio was optimal.
  • Fibrosis Induction: Cardiac fibrosis was induced by treating the CTCs with Transforming Growth Factor-beta 1 (TGF-β1) at a concentration of 2 ng/mL.
  • Drug Testing: The anti-fibrotic drug pirfenidone was tested by adding it to the culture medium, both in the presence and absence of TGF-β1.
  • Readouts: The effects of TGF-β1 and pirfenidone were assessed using:
  • RT-qPCR: To measure the mRNA expression of fibrotic markers (e.g., POSTN, α-SMA, COL1a1, COL3).
  • Immunofluorescence Microscopy: To visualize the spatial distribution and expression of key proteins like α-SMA and periostin.
  • Targeted Proteomics (Olink Cardiovascular Panel 3): A novel approach to simultaneously measure the protein levels of 92 cardiovascular disease-related proteins, providing a deeper mechanistic understanding.
  • Cell Viability Assays: To ensure the model and treatments did not compromise cell health.
  • Calcium Transient Imaging: To assess the functional electrical activity of the cardiomyocytes.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • A Tunable 3D Model for Cardiac Fibrosis: The development of a mechanically tunable 3D hydrogel model using hiPSC-CMs and hfCFs is a significant advancement. This model not only recapitulates key aspects of human cardiac fibrosis but also allows for precise control over the mechanical environment, which is known to influence cell behavior.
  • Functional Integration of Cardiomyocytes and Fibroblasts: Achieving synchronous beating in the 3D constructs is a critical indicator of successful cell-cell communication and functional tissue development. This highlights the importance of co-culturing these cell types in a suitable 3D environment for accurate disease modeling.
  • Pirfenidone's Anti-fibrotic Potential in Human Cardiac Context: The study provides compelling evidence that pirfenidone has anti-fibrotic effects in a human cardiac model in vitro. This is crucial for translating findings from animal studies to human-relevant systems.
  • Mechanistic Insights into Pirfenidone's Action: By using targeted proteomics, the researchers identified specific proteins affected by pirfenidone. The drug reduced the expression of key fibrotic proteins like COL1a1 and MMP2, and also impacted heart failure-associated proteins like OPG and IGFBP7.
  • Partial Efficacy of Pirfenidone: A key finding is that pirfenidone, while beneficial, does not completely reverse all TGF-β1-induced fibrotic changes. Specifically, it did not affect the expression of plasminogen-related proteins (PAI, uPA, U-PAR) that were upregulated by TGF-β1. This suggests that pirfenidone might primarily target the canonical TGF-β pathway, leaving non-canonical pathways less affected.

Key Results

  • TGF-β1 Induction of Fibrosis: TGF-β1 treatment significantly increased the mRNA expression of fibrotic markers: POSTN (2.5-fold), α-SMA (2.0-fold), COL1a1 (1.5-fold), and COL3 (1.5-fold). Immunofluorescence confirmed increased α-SMA and periostin.
  • Proteomic Changes with TGF-β1: Targeted proteomics revealed increased protein expression of COL1a1, MMP2, OPG, IGFBP7, PAI, uPA, and U-PAR upon TGF-β1 stimulation.
  • Pirfenidone's Effect on mRNA (without TGF-β1): In the absence of TGF-β1, pirfenidone significantly reduced POSTN, COL1a1, and COL3 mRNA expression.
  • Pirfenidone's Effect on Protein (with and without TGF-β1): Pirfenidone treatment led to a decrease in COL1a1, MMP2, OPG, and IGFBP7 protein expression, regardless of TGF-β1 presence.
  • Pirfenidone's Limited Effect on Certain Proteins: Pirfenidone did not significantly alter the expression of PAI, uPA, and U-PAR, even when TGF-β1 was present.
  • Cell Viability: Cells maintained excellent viability (around 80-97%) in the 7.5% GelMA hydrogels for up to 14 days.

Limitations and Future Work

  • Model Limitations: While the model is advanced, it is still an in vitro system. The complex interplay of various cell types, immune cells, and the dynamic in vivo environment are not fully replicated. The study also used fetal cardiac fibroblasts, and future work could explore using iPSC-derived cardiac fibroblasts for a more patient-specific approach.
  • Pirfenidone's Mechanism: The study suggests pirfenidone targets the canonical TGF-β pathway but not non-canonical ones. Future research could further elucidate these specific pathways and identify the precise molecular targets.
  • Drug Efficacy in Complex Scenarios: The study focused on pirfenidone's effect on TGF-β1-induced fibrosis. Future work could investigate its efficacy in models of other fibrotic stimuli or in combination with other drugs.
  • Translational Potential: While this model is a step towards better drug testing, further validation and correlation with clinical outcomes will be necessary to fully realize its translational potential. The authors suggest that such models are crucial for bridging the gap between preclinical findings and clinical efficacy, especially for complex conditions like cardiac fibrosis.

Summary updated

Abstract

A fundamental process in the development and progression of heart failure is fibrotic remodeling, characterized by excessive deposition of extracellular matrix proteins in response to injury. Currently, therapies that effectively target and reverse cardiac fibrosis are lacking, warranting novel therapeutic strategies and reliable methods to study their effect. Using a gelatin methacryloyl hydrogel, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and human fetal cardiac fibroblasts (hfCF), we developed a multi-cellular mechanically tunable 3D <i>in vitro</i> model of human cardiac fibrosis. This model was used to evaluate the effects of a promising anti-fibrotic drug-pirfenidone-and yields proof-of-concept of the drug testing potential of this platform. Our study demonstrates that pirfenidone has anti-fibrotic effects but does not reverse all TGF-β1 induced pro-fibrotic changes, which provides new insights into its mechanism of action.
BibTeX
@inproceedings{gartner2022pirfenidone,
  author = {Thomas Gärtner and Sandra Crnko and Laurynas Leiteris and Iris van Adrichem and Linda W. van Laake and Carlijn V. C. Bouten and Marie‐José Goumans and Willem J.L. Suyker and Joost P. G. Sluijter and Jesper Hjortnaes},
  title = {{Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2022},
  doi = {10.3389/fcvm.2022.854314},
}
Figure